clinical trial · NCT07108153
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Cystic Fibrosis (CF)SION-719Placebo-to-match SION-719
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.
started
Nov 3, 2025
primary completion
Jul 1, 2026
completion
Jul 1, 2026
last updated
Mar 2, 2026
official title
A Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed Trikafta® in People With Cystic Fibrosis Who Are Homozygous for the F508del Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol